Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors
- PMID: 7783912
- DOI: 10.1212/wnl.45.6_suppl_6.s44
Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors
Abstract
Multiple sclerosis (MS) is a demyelinating disease in which an inflammatory cell infiltrate represents a characteristic pathologic feature of active lesions within the CNS. The possibility has been raised that cell-mediated immune mechanisms orchestrate the pathogenesis of MS. Cytokines play a particularly important role in cellular immune mechanisms. These soluble glycoproteins, nonimmunoglobulin in nature, act nonenzymatically to regulate immune cell function. A unique family of cytokines, the tumor necrosis factors (TNFs), demonstrate immunoregulatory activity but are also involved in the effector arm of cellular immune responses. Recently, studies both in vitro and in vivo have suggested a role for TNFs in the pathology of MS. This report summarizes data implicating TNFs in the mechanisms of MS and attempts to apply the anti-TNF approach in the future therapeutic strategy for this disease.
Similar articles
-
Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system.Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i94-102. doi: 10.1136/ard.59.suppl_1.i94. Ann Rheum Dis. 2000. PMID: 11053098 Free PMC article. Review. No abstract available.
-
Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis.Immunol Res. 2003;28(1):61-78. doi: 10.1385/IR:28:1:61. Immunol Res. 2003. PMID: 12947225 Review.
-
Identification of new therapeutic targets for prevention of CNS inflammation.Expert Opin Ther Targets. 2002 Apr;6(2):203-15. doi: 10.1517/14728222.6.2.203. Expert Opin Ther Targets. 2002. PMID: 12223081 Review.
-
Tumor necrosis factor and motoneuronal degeneration: an open problem.Neuroimmunomodulation. 2001;9(4):178-82. doi: 10.1159/000049024. Neuroimmunomodulation. 2001. PMID: 11847479 Review.
-
Temporal kinetics and cellular phenotype of TNF p55/p75 receptors in experimental allergic encephalomyelitis.J Neuroimmunol. 1999 Mar 1;95(1-2):19-34. doi: 10.1016/s0165-5728(98)00258-6. J Neuroimmunol. 1999. PMID: 10229112
Cited by
-
Immunogenicity and other problems associated with the use of biopharmaceuticals.Ther Adv Drug Saf. 2011 Jun;2(3):113-28. doi: 10.1177/2042098611406318. Ther Adv Drug Saf. 2011. PMID: 25083207 Free PMC article. Review.
-
New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.Clin Rheumatol. 2013 Feb;32(2):271-5. doi: 10.1007/s10067-012-2113-2. Epub 2012 Nov 14. Clin Rheumatol. 2013. PMID: 23149905 Review.
-
Astrocyte TNFR2 is required for CXCL12-mediated regulation of oligodendrocyte progenitor proliferation and differentiation within the adult CNS.Acta Neuropathol. 2012 Dec;124(6):847-60. doi: 10.1007/s00401-012-1034-0. Epub 2012 Aug 30. Acta Neuropathol. 2012. PMID: 22933014 Free PMC article.
-
LRP1 expression in microglia is protective during CNS autoimmunity.Acta Neuropathol Commun. 2016 Jul 11;4(1):68. doi: 10.1186/s40478-016-0343-2. Acta Neuropathol Commun. 2016. PMID: 27400748 Free PMC article.
-
Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function.Neuromuscul Disord. 2014 Jul;24(7):583-95. doi: 10.1016/j.nmd.2014.04.006. Epub 2014 Apr 26. Neuromuscul Disord. 2014. PMID: 24844454 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical